Dr. Eaglstein is a medical graduate of the University of Missouri, Columbia. After an internship at Kings County Hospital in Brooklyn he completed his dermatology training at the University of Miami follow which he served in the U.S. Navy Medical Corps. He is a past professor and chairman of dermatology at the University of Pittsburgh and the University of Miami, where he is currently chairman emeritus. Since 2004 he has worked in industry at Ivax Pharmaceuticals( President of Ivax Derm), Teva and Stiefel Pharmaceuticals ( Vice President of Research ) and Stiefel a GSK company (Vice President of New Product Assessment and External Research). He is currently an independent consultant, serves on the National Institutes of Arthritis, Musculoskeletal and Skin (NIAMS) Clinical Trials Review Committee and is a volunteer for the Stanford School of Medicine SPARK program. Dr. Eaglstein has been a Robert Wood Johnson Health Policy Fellow, Chairman of an FDA skin advisory panel, Consultant to the FDA OTC division and on the NIAMS NIH National Advisory Panel. He continues his interest in health and regulatory policy. His medical/scientific interests include wound healing, wound care, drug development, skin infections, UV inflammation and inflammatory diseases such as psoriasis and acne.

Provides readers with an in-depth understanding of the FDA and those issues related to their practice and to society in general

Represents an introductory overview written from a physician's perspective for physicians

Contains detailed explanation of nomenclature and definitions

Introduction - The FDA, Doctors and the Practice of Medicine.- Drugs.- Devices.- Biologics.- Combination Products.- Supplements and Neutraceuticals.- Foods.- Cosmetics and Cosmeceuticals.- The FDA (history, organization, budgets).- The Approval Process (including Phases 1-4, advisory committees, Guidances and personal medicine).- The FDA and Promotion and Advertising.- The FDA and Drug Names.- The FDA , Politics and the Public.